Advertisement
Singapore markets close in 46 minutes
  • Straits Times Index

    3,279.10
    -8.65 (-0.26%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,668.23
    +383.69 (+2.22%)
     
  • FTSE 100

    8,122.37
    +43.51 (+0.54%)
     
  • Bitcoin USD

    64,384.06
    +334.54 (+0.52%)
     
  • CMC Crypto 200

    1,387.74
    -8.79 (-0.63%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,359.00
    +16.50 (+0.70%)
     
  • Crude Oil

    84.00
    +0.43 (+0.51%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,573.84
    +4.59 (+0.29%)
     
  • Jakarta Composite Index

    7,068.28
    -87.01 (-1.22%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Why Ibrance Is a Major Growth Driver for Pfizer

Why Ibrance Is a Major Growth Driver for Pfizer

Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Recent Ibrance approval On April 4, Pfizer (PFE) issued a press release announcing the FDA’s approval of its leading CDK4/6 (cyclin-dependent kinase 4/6) inhibitor